Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

MR-Linac adaptive radiotherapy plus temozolomide reduces CTV margins in high-grade glioma, according to results from the phase 2 UNITED trial.

MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma

Patients with WHO grade II/III recurrent meningioma experienced clinically meaningful efficacy with 177Lutetium-Dotatate.

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma 

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Articles

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Joseph M. Scandura, MD, PhD, discusses the importance of research with single-agent selinexor in JAK inhibitor–naive myelofibrosis. 

Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Nitin Jain, MD, discusses the use of BTK inhibitor– and venetoclax-based regimens for the frontline treatment of chronic lymphocytic leukemia. 

BTK Inhibitors vs Venetoclax: Considerations for Frontline Treatment Selection in CLL

Dana-Farber Cancer Institute has used weighted blankets to aid in patient care.

Dana-Farber Cancer Institute Delivers ‘Simple Immediate Impact’ to Patient Comfort Using Weighted Blankets

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

The EMA has received a submission seeking the approval of darolutamide in combination with ADT in metastatic hormone-sensitive prostate cancer.

EU Approval Sought for Darolutamide Plus ADT for mHSPC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Clinical Updates in Treating Advanced Prostate Cancer

Recent Data on ARPI-Based Combination Regimens

If you have a patient who comes to your clinic and they are coming in for a second opinion to ensure optimized therapy, do you ever offer 6 cycles of docetaxel?

Videos

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

Treatment Landscape and Sequencing of Therapies

Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.

Treatment Timelines Related to Disease State and Use of Monotherapy

Panelists discuss how genetic testing for germline mutations is becoming increasingly crucial in the management of prostate cancer, enabling personalized treatment approaches and informing patient care decisions.

Genetic Testing – Germline

Panelists discuss how recent data on androgen receptor pathway inhibitor–based combination regimens highlight their potential to enhance treatment outcomes for advanced prostate cancer, underscoring the importance of integrating these findings into clinical practice.

Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.

Genetic Testing – Somatic

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.

ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

Recent Data on ARPI-Based Combination Regimens

EP: 1.Treatment Landscape and Sequencing of Therapies

EP: 2.Treatment Timelines Related to Disease State and Use of Monotherapy

EP: 3.Genetic Testing – Germline

EP: 4.Recent Data on ARPI-Based Combination Regimens

EP: 5.Genetic Testing – Somatic

EP: 6.ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

Latest Conference Coverage